Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa (NCT06079372)
A Phase 3, Randomized, Open-label, Parallel-arm, Active-controlled, Multicenter Study to Evaluate Safety and Efficacy of ALXN1850 Versus Asfotase Alfa Administered Subcutaneously in Pediatric Participants (2 to < 12 Years of Age) With Hypophosphatasia (HPP) Previously Treated With Asfotase Alfa
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of this study is to assess the safety and tolerability of ALXN1850 versus asfotase alfa in pediatric participants with HPP previously treated with asfotase alfa.
Who can join: Review the eligibility criteria below.
Location: Research Site — Hartford, Connecticut
Age range: 2 Years to 11 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- Research Site — Hartford, Connecticut
- Research Site — Baltimore, Maryland
- Research Site — Minneapolis, Minnesota
- Research Site — Kansas City, Missouri
- Research Site — Durham, North Carolina
- Research Site — Nashville, Tennessee
- Research Site — Mar del Plata,
- Research Site — South Brisbane,
- Research Site — Ottawa, Ontario
- Research Site — Bunkyō City,
- Research Site — Minatoku,
- Research Site — Suita-shi,
- Research Site — Yonago-shi,
- Research Site — Altındağ,
- Research Site — Ankara,
- Research Site — Edirne,
- Research Site — Erzurum,
- Research Site — Istanbul,
- Research Site — Birmingham,
- Research Site — Manchester,
- Research Site — Sheffield,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hypophosphatasia
- Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa — Indianapolis, Indiana
- Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP — Baltimore, Maryland
- Natural History Study of Patients With Hypophosphatasia (HPP) — Durham, North Carolina
- A Prospective Sub-Study of the Global Hypophosphatasia Registry — Hartford, Connecticut
Explore by condition: All Hypophosphatasia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.